US Patent Issued to Amgen on March 4 for "Process for generating genetically engineered autologous T cells" (California Inventors)

ALEXANDRIA, Va., March 5 -- United States Patent no. 12,241,086, issued on March 4, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Process for generating genetically engineered autologous T cells" was invented by Yijun Liu (Camarillo, Calif.), Kathryn Anne Henckels (Thousand Oaks, Calif.) and Carlos Arbelaez (Thousand Oaks, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to production of autologous genetically engineered T cells for use in cell therapy applications."

The patent was filed on April 15, 2020, under Application No. 16/849,023.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PT...